How a pharmacy makes money now the prices are showing

A pharmacy lives on the gap between what it pays for a box and what it charges, and the fattest gap has tended to be on medicines nobody thinks to compare. A price list doesn't close that by itself. My guess is it mostly changes which box gets picked up.

I couldn't find one independent Malaysian pharmacy's margin, so what follows is one old study, one big chain and some reasoning.

What actually came into view

Less than the headlines suggest. The Price Marking for Drug Order took effect in May 2025, and as lawyers summarised it, shelf items need a price tag, and anything kept out of sight needs a list.¹ That list gives the generic name, the trade name and the price per unit.¹

The shelf was never where the mystery was, at least not for me. A box I can pick up is a box I can price in the shop next door, tag or no tag.

So the new bit is the list. That's the medicine you used to have to ask about.

Whether anyone's made to keep it up is messier. Doctors' groups won a High Court stay in May 2026, and the Malaysian Medical Association said in August 2026 that it held for private healthcare facilities while the case goes on.⁵ The reports I could read don't mention pharmacies, so I'm assuming they remain bound, and I could be wrong.

Clinics had their own reason to mind, and that's most of why your GP's fee stayed stuck for so long.

Where the gap was

The best study I can find is old. A paper in PLoS Medicine, published in 2007, surveyed medicine prices across West Malaysia, including at 32 private pharmacies, and along the way worked out the markups on five medicines in Kuala Lumpur.³

Markup on a box, top of each range, in percent

That looks like a scandal for a second. It isn't quite one, because percentages flatter a cheap box.

Say a shop pays forty ringgit for the brand and sells it at fifty-two. Say it pays eight for the generic and sells it at eighteen. Both figures are made up, but they sit inside that study's ranges, and notice what happens: the generic has the huge markup, and the brand still keeps more ringgit.

The authors suggest that generics get priced with the original brand as a ceiling.³ That rings true to me. A generic isn't priced at what it costs, it's priced at some comfortable distance below the famous one.

Why the list changes less than it should

An original brand is the same box everywhere, so it's easy to compare. I'd expect those margins to get squeezed first, and they were the thin ones anyway.

A generic is harder. Two shops may stock different makers under names you've never seen, so you'd have to compare by active ingredient, per unit, across two lists. The Order makes that possible, and I'd guess a handful of determined people will do it.¹

The more interesting comparison is inside one shop. The list now puts the generic next to the brand, and I think that's where behaviour shifts.

In my made-up example, the customer saves thirty-four ringgit and the shop gives up two. If my sums are anywhere near right, a pharmacist has little reason to resist that swap.

What the shop is living on

Volume, for a start. Big Caring, the largest chain, had 626 outlets when it filed its draft listing prospectus, with revenue of RM3.41 billion for the year to June 2025.⁴ Net profit was RM143.02 million, or about four sen on the ringgit by my sum.⁴

It's carrying debts from buying rivals, so that's not a clean picture of running shops. But it's a useful thing to say at dinner: the biggest pharmacy group in the country keeps about four sen of your ringgit.

Then there's everything that isn't medicine, or isn't on that list. You go in for one strip of antihistamines and leave past a wall of vitamins and shampoo. I don't know how much of the vitamin wall the Order catches, and I couldn't find a Malaysian figure for what those shelves earn, but nobody has memorised what a bottle should cost.

Own-label products are the obvious next move for anyone with the scale, since nobody can check an own label against the shop next door. I'd guess they pay better, and I can't prove it.

Where a small pharmacy's ringgit goes, my rough guess

The independent's problem

The Order defines a community pharmacy as a place with at least one pharmacist holding a Type A licence.¹ So that salary is fixed before the first box is sold, whether it's a busy month or not.

And her advice is paid for by the box. CodeBlue reported in May 2025 that pharmacists can't charge dispensing or professional fees, and that their society wanted them brought in, with a shift away from "profit-margin models".²

So the free conversation about whether two medicines clash is funded by the markup that the list is shining a light on. That was the part of this that surprised me.

A chain can buy cheaper and shrug. The independent can't win on the box with the famous name, so I'd stop trying and compete on what's harder to put on a list: knowing the customer, her mother's prescriptions, and which generic she can tolerate.